SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-19-076187
Filing Date
2019-12-26
Accepted
2019-12-26 16:51:23
Documents
14
Period of Report
2019-12-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm1926743-1_8k.htm   iXBRL 8-K 29026
2 EXHIBIT 99.1 tm1926743d1_ex99-1.htm EX-99.1 21616
6 GRAPHIC tm1926743d1_ex99-1img001.jpg GRAPHIC 10843
  Complete submission text file 0001104659-19-076187.txt   248957

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tbph-20191221.xsd EX-101.SCH 3192
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20191221_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20191221_pre.xml EX-101.PRE 22714
14 EXTRACTED XBRL INSTANCE DOCUMENT tm1926743-1_8k_htm.xml XML 3625
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 191310941
SIC: 2834 Pharmaceutical Preparations